AstraZeneca acquires a Chinese cancer drug developer with a transaction value of approximately $1.2 billion
白云追月素
发表于 2023-12-26 20:35:32
273
0
0
AstraZeneca announced on Tuesday local time that a final agreement has been signed on the proposed acquisition of Gracell, which will add GC012F CAR-T cell therapy to AstraZeneca's expanding cell therapy pipeline.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Yum China announces share buyback plan involving approximately $360 million
- Yum China announces plans to repurchase approximately $360 million worth of shares
- General Motors China responds to rumors of 'General Motors plans to restructure its business in China'
- Starbucks' '' China Anxiety '
- The three major indexes of the US stock market collectively closed down, while the Nasdaq China Golden Dragon Index rose more than 8% and tripled. Go long, FTSE China ETF rose nearly 24%
- Global market: Chinese assets explode, China Golden Dragon Index rises 8.54%, 3-fold long, FTSE China ETF rises nearly 24%
- China's US Treasury holdings hit the lowest level in over 15 years in October! Is the wave of US debt reduction spreading globally?
- What is the impact of the Biden administration's 301 investigation on China's mature process chip industry?
- Lilly weight loss pills are now available for purchase on e-commerce platforms. Lilly China responds that they are self funded drugs
- Chinese assets suddenly exploded! Multiple Chinese concept stocks rose by over 10%
